This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gillam, M. P. Articles by Molitch, M. E. Search for Related Content PubMed PubMed Citation Articles by Gillam, M. P. Articles by Molitch, M. E.

The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma

Division of Endocrinology, Metabolism, and Molecular Medicine (M.P.G., M.E.M.), Northwestern University, The Feinberg Medical School, Chicago, Illinois 60611; and Cedars-Sinai Medical Center (S.M.), University of California at Los Angeles School of Medicine, Los Angeles, California 90048

Address all correspondence and requests for reprints to: Mark E. Molitch, M.D., Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University, The Feinberg Medical School, 303 East Chicago Avenue, Tarry 15, Chicago, Illinois 60611. E-mail: molitch{at}northwestern.edu.

Abstract

Most prolactinomas respond rapidly to low doses of dopamine agonists. Occasionally, stepwise increases in doses of these agents are needed to achieve gradual prolactin (PRL) reductions. Approximately 50% of treated men remain hypogonadal, yet testosterone replacement may stimulate hyperprolactinemia.

A 34-yr-old male with a pituitary macroadenoma was found to have a PRL level of 10,362 µg/liter and testosterone level of 3.5 nmol/liter. Eleven months of dopamine agonist therapy at standard doses lowered PRL levels to 299 µg/liter. Subsequent stepwise increases in cabergoline (3 mg daily) further lowered PRL levels to 71 µg/liter, but hypogonadism persisted. Initiation of testosterone replacement resulted in a rise and discontinuation in a fall of PRL levels. Aromatization of exogenous testosterone to estradiol and subsequent estrogen-stimulated PRL release was suspected. Concomitant use of cabergoline with the aromatase inhibitor anastrozole after resuming testosterone replacement resulted in the maintenance of testosterone levels and restoration of normal sexual function, without increasing PRL. Ultimately, further reduction in PRL on this therapy permitted endogenous testosterone production. Thus, novel pharmacological maneuvers may permit successful medical treatment of some patients with invasive macroprolactinomas.

This article has been cited by other articles:

				J. A. Schlechte Long-Term Management of Prolactinomas J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2861 - 2865. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				E. Delgrange, A. Pinero, P. Marcos-Alberca, and J. Fortes Cabergoline and Mitral Regurgitation N. Engl. J. Med., January 26, 2006; 354(4): 420 - 420. [Full Text] [PDF]